5-alpha reductase inhibitor

This page covers all 5-alpha reductase inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting 5-alpha reductase (type 1 and type 2), 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1, Cytochrome P450 2C19, Cytochrome P450 2C9, 5-alpha reductase.

Targets

5-alpha reductase (type 1 and type 2) · 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1, Cytochrome P450 2C19, Cytochrome P450 2C9 · 5-alpha reductase · 5-alpha-reductase

Marketed (3)

• Dutasteride Capsules · UConn Health · Urology
  Dutasteride inhibits both type 1 and type 2 5-alpha reductase enzymes, blocking the conversion of testosterone to dihydrotestosterone (DHT) and reducing DHT levels in the prostate.
• Pre-randomization Dutasteride · Siami, Paul F., M.D. · Urology
  Dutasteride inhibits both type 1 and type 2 5-alpha reductase enzymes, blocking the conversion of testosterone to dihydrotestosterone (DHT).
• Propecia · Merck & Co. · Urology
  Selective type II 5-alpha-reductase inhibitor that blocks conversion of testosterone to dihydrotestosterone (DHT), treating BPH and male pattern hair loss.

Phase 2 pipeline (2)

• CB-03-01 · Intrepid Therapeutics, Inc. · Dermatology
  CB-03-01 is a selective androgen receptor modulator (SARM) that inhibits 5-alpha reductase to reduce DHT-driven androgenetic alopecia.
• 5ARI · GlaxoSmithKline · Urology
  5-alpha-reductase inhibitor